The regulatory strategy is the best pathway to draw up suitable development plans.

The experience of Asphalion team allows the selection of best regulatory strategy from all existing possibilities.

Strategic inputs can be given from the very beginning for segmentation/niche indication, conditional approval/fast track, orphan drug designations, preclinical and clinical plans with minimum time-to-market, and others.

Roadmaps: non-clinical and clinical development plans, including assessment of feasibility, strategy, timelines and costs

Scientific Advice: expertise for optimal outcome with EMA, EU-NCAs, FDA and other agencies

• Paediatric Investigation Plan (PIP)
• Orphan Drug Designation (ODD)
• Clinical Trial Application (CTA)
• Investigational Medicinal Product Dossier (IMPD)
• Investigator’s Brochure (IB)
• Regulatory Partner for Horizon 2020 Program

Asphalion has already worked in 15 successful PIPs and 20 ODDs, along with Parallel FDA and EU submission for Fast Track / Conditional Approval. Our experts have participated in Scientific advice with EMA as well as National Competent Authorities such as, PEI, AEMPS, DKMA, CbG, MPA, among others. We have been involved in the UAT of EMA for the new CT portal, and worked with EudraCT  and clinicaltrials.gov.

Besides, Asphalion is currently member of 8 prosperous consortiums of Horizon 2020 European Commission program: iHIVARNA, MYOCURE, ELASTISLET, iHIVACAR, nTRACK , CardioReGenix, SBR and MISTRAL.